Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | TBXAS1 | P24557 | 5/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | QPCT | Q16769 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15190312 | 0.90 | HPGD (0.69) | SMN1; SMN2MEN1KMT2AQPCTGAA | |
| SCHEMBL9271796 | 0.84 | HPGD (0.78) | SMN1; SMN2MEN1KMT2AALDH1A1GAA | |
| SCHEMBL14255017 | 0.82 | TBXAS1 (0.66) | SMN1; SMN2TBXAS1MEN1KMT2AQPCT | |
| SCHEMBL14255015 | 0.82 | TBXAS1 (0.66) | SMN1; SMN2TBXAS1MEN1KMT2AQPCT | |
| SCHEMBL10247217 | 0.81 | SMN1; SMN2 (0.62) | SMN1; SMN2TBXAS1QPCTALDH1A1GAA | |
| Hydrochloric Acid SCHEMBL411425 | 0.80 | SMN1; SMN2 (0.61) | SMN1; SMN2TBXAS1QPCTALDH1A1GAA | |
| SCHEMBL10853278 | 0.80 | SMN1; SMN2 (0.68) | SMN1; SMN2MEN1KMT2AQPCTALDH1A1 | |
| SCHEMBL2942358 | 0.78 | MEN1 (0.96) | SMN1; SMN2MEN1KMT2AALDH1A1GAA | |
| SCHEMBL10819292 | 0.77 | SMN1; SMN2 (0.71) | SMN1; SMN2MEN1KMT2AQPCTALDH1A1 | |
| SCHEMBL77556 | 0.76 | QPCT (1.00) | SMN1; SMN2QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4532268-A | Imidazole agent for retarding the polymerization of aziridine compounds | ESPE, FABRIK PHARMAZEUTISCHER PRAPARATE GMBH (DE) | 1985-07-30 | — | — | US | claimed |
| EP-3883522-B1 | USE OF A POLYETHER-MODIFIED POLYDIMETHYL SILOXANE FOR REDUCING THE STICKINESS OF A DENTAL IMPRESSION COMPOSITION | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240285476-A1 | DENTAL COMPOSITION COMPRISING AN ISORBIDE COMPONENT | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2024-08-29 | — | — | US | disclosed |
| EP-4346741-A1 | DENTAL COMPOSITION COMPRISING AN ISORBIDE COMPONENT | Solventum Intellectual Properties Company (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2022248954-A1 | DENTAL COMPOSITION COMPRISING AN ISORBIDE COMPONENT | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2022-12-01 | — | — | WO | disclosed |
| EP-3883522-A1 | CURABLE COMPOSITION CONTAINING A POLYETHER-MODIFIED POLYDIMETHYL SILOXANE | 3M Innovative Properties Company (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-2613754-B1 | CURABLE COMPOSITION, PROCESS OF PRODUCTION AND USE THEREOF | 3M INNOVATIVE PROPERTIES CO (US) | 2018-10-17 | — | — | EP | disclosed |
| US-9216141-B2 | Curable composition, process of production and use thereof | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-12-22 | — | — | US | disclosed |
| US-20130157226-A1 | CURABLE COMPOSITION, PROCESS OF PRODUCTION AND USE THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2428199-A1 | Curable composition, process of production and use thereof | 3M Innovative Properties Company (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-0110429-B1 | RETARDERS FOR THE POLYMERISATION OF AZIRIDINE COMPOUNDS | ESPE Stiftung & Co Produktions- und Vertriebs KG (DE) | 1990-01-17 | — | — | EP | disclosed |
| US-4532268-A | Imidazole agent for retarding the polymerization of aziridine compounds | ESPE, FABRIK PHARMAZEUTISCHER PRAPARATE GMBH (DE) | 1985-07-30 | — | — | US | disclosed |
| EP-0110429-A2 | Retarders for the polymerisation of aziridine compounds | ESPE Stiftung & Co Produktions- und Vertriebs KG (DE) | 1984-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240285476-A1 | DENTAL COMPOSITION COMPRISING AN ISORBIDE COMPONENT | INTS9, PUF60, TAS2R42 | SMN1; SMN2 3399/4885TBXAS1 3950/4885MEN1 578/4885 |
| US-20130157226-A1 | CURABLE COMPOSITION, PROCESS OF PRODUCTION AND USE THEREOF | LDHA, LDHB, SOD1 | SMN1; SMN2 1718/4885TBXAS1 3523/4885MEN1 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.